Lipids News and Research

RSS

Lipids are a broad group of naturally-occurring molecules which includes fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K), monoglycerides, diglycerides, phospholipids, and others. The main biological functions of lipids include energy storage, as structural components of cell membranes, and as important signaling molecules.

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Breastfeeding a child may lower a woman's risk of developing Metabolic Syndrome

Breastfeeding a child may lower a woman's risk of developing Metabolic Syndrome, a condition linked to heart disease and diabetes in women, according to a Kaiser Permanente study that was published today online ahead of print and will appear in the February issue of Diabetes, a journal of the American Diabetes Association.

4 Dec 2009

Breastfeeding reduces a woman's risk of developing Metabolic Syndrome

3 Dec 2009

Research study compares genetic make-up of humans and primates

In spite of their genetic similarity to humans, chimpanzees and great apes have maximum lifespans that rarely exceed 50 years. The difference, explains USC Davis School of Gerontology Professor Caleb Finch, is that as humans evolved genes that enabled them to better adjust to levels of infection and inflammation and to the high cholesterol levels of their meat rich diets.

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

The DFG has approved the establishment of 17 new Collaborative Research Centres as of 1 January 2010. This decision was made recently by the relevant Grants Committee in Bonn.

1 Dec 2009

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc., today presented additional clinical data for lubiprostone (Amitiza®) at GASTRO 2009 UEGF/WCOG, the joint meeting of the United European Gastroenterology Federation (UEGF), the World Gastroenterology Organisation (WGO), the World Organisation of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG), in London.

25 Nov 2009

Study: Impaired oxidation in liver associated with progression to nonalcoholic steatohepatitis

A recent metobolomics study by researchers from Virginia Commonwealth University Medical Center in Richmond found that impaired peroxisomal oxidation of polyunsaturated fatty acids (PUFA) is associated with the progression of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH).

24 Nov 2009

Research suggests common oral bacterium may exacerbate autoimmune disease

Current research suggests that a common oral bacterium may exacerbate autoimmune disease. The related report by Nichols et al, "Unique Lipids from a Common Human Bacterium Represent a New Class of TLR2 Ligands Capable of Enhancing Autoimmunity," appears in the December 2009 issue of The American Journal of Pathology.

23 Nov 2009

Obesity: A major contributor to the development of Type 2 diabetes

"Many Americans have a very limited understanding of the basic facts about diabetes, as well as the serious consequences for health that accompany the disease," commented Sue McLaughlin, RD, CDE, President, Health Care & Education, American Diabetes Association, in a media alert. She blames the problem on a combination of factors including denial of the disease and promotion of inaccurate information or myths surrounding diabetes.

21 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

Swissmedic grants marketing authorization for Amitiza

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).

20 Nov 2009

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

PanGenex finalizes partnership with BulovaTech Labs

PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., (“LABS”), a wholly-owned subsidiary of Bulova Technologies Group Inc.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

Lipid that accumulates in brain cells drives cell death, says research

The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.

13 Nov 2009

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%.

12 Nov 2009